Universidad Peruana Cayetano Heredia
Successful treatment of drug-resistant cutaneous leishmaniasis in humans by use of imiquimod, an immunomodulator
JavaScript is disabled for your browser. Some features of this site may not work without it.
Mostrar el registro sencillo del ítem
| dc.contributor.author | Arevalo, I. | |
| dc.contributor.author | Ward, B. | |
| dc.contributor.author | Miller, R. | |
| dc.contributor.author | Meng, T. | |
| dc.contributor.author | Najar Trujillo, Nestor Enrique | |
| dc.contributor.author | Alvarez, Eugenia | |
| dc.contributor.author | Matlashewski, G. | |
| dc.contributor.author | Llanos Cuentas, Elmer Alejandro | |
| dc.date.accessioned | 2022-10-25T19:54:11Z | |
| dc.date.available | 2022-10-25T19:54:11Z | |
| dc.date.issued | 2001 | |
| dc.identifier.uri | https://hdl.handle.net/20.500.12866/12484 | |
| dc.description.abstract | Treatment failures for leishmaniasis with pentavalent antimonials, including meglumine antimonate, are increasingly common in many endemic areas. Imiquimod (Aldara; 3M Pharmaceuticals) is a novel immune response-activating compound, approved by the United States Food and Drug Administration, that is currently used to treat cervical warts and has been shown to activate macrophage killing of Leishmania species. Therefore, an open-label, prospective study was conducted of combined imiquimod plus meglumine antimonate therapy in 12 patients with cutaneous leishmaniasis who had previously not responded to meglumine antimonate therapy. All of the patients responded well to this combination therapy, and 90% were found to be cured at the 6-month follow-up period. | en_US |
| dc.language.iso | eng | |
| dc.publisher | Oxford University Press | |
| dc.relation.ispartofseries | Clinical Infectious Diseases | |
| dc.rights | info:eu-repo/semantics/restrictedAccess | |
| dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es | |
| dc.subject | Drug-Resistant | en_US |
| dc.subject | Imiquimod | en_US |
| dc.subject | Immunomodulator | en_US |
| dc.title | Successful treatment of drug-resistant cutaneous leishmaniasis in humans by use of imiquimod, an immunomodulator | en_US |
| dc.type | info:eu-repo/semantics/article | |
| dc.identifier.doi | https://doi.org/10.1086/324161 | |
| dc.subject.ocde | https://purl.org/pe-repo/ocde/ford#3.03.08 | |
| dc.relation.issn | 1537-6591 |
Ficheros en el ítem
| Ficheros | Tamaño | Formato | Ver |
|---|---|---|---|
|
No hay ficheros asociados a este ítem. |
|||
Este ítem aparece en la(s) siguiente(s) colección(ones)
-
Artículos en revistas indizadas [4988]
Recuperados de bases de datos bibliográficas
Excepto si se señala otra cosa, la licencia del ítem se describe como info:eu-repo/semantics/restrictedAccess
